(Total Views: 598)
Posted On: 05/17/2021 3:46:11 PM
Post# of 151881

Re: craigakess #90451
The FDA is correct in that the endpoints failed. Of course no explanation by the FDA of why the endpoints failed including the FDA not allowing us 4 doses in the severe/critical trial. We know leronlimab is showing clinical benefit and the FDA will be backpedaling after the Brazil trials.


Scroll down for more posts ▼